The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off

Masclee, Gwen; Coloma, Preciosa M.; Wilde, Marcel de; Kuipers, Ernst J.; Sturkenboom, Miriam

doi:10.1111/apt.12759

Cited by 44 publications

(33 citation statements)

References 30 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of patients present with advanced disease, and the overall survival is <15% despite advances in multimodal therapy (Jemal et al 2011;Masclee et al 2014). Patients who do not have distant nodal or organ metastases are considered suitable for treatment with curative intent.…”

mentioning

confidence: 99%

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy

et al. 2017

View full text Add to dashboard Cite

The scientific community has avoided using tissue samples from patients that have been exposed to systemic chemotherapy to infer the genomic landscape of a given cancer. Esophageal adenocarcinoma is a heterogeneous, chemoresistant tumor for which the availability and size of pretreatment endoscopic samples are limiting. This study compares whole-genome sequencing data obtained from chemo-naive and chemo-treated samples. The quality of whole-genomic sequencing data is comparable across all samples regardless of chemotherapy status. Inclusion of samples collected post-chemotherapy increased the proportion of late-stage tumors. When comparing matched pre-and post-chemotherapy samples from 10 cases, the mutational signatures, copy number, and SNV mutational profiles reflect the expected heterogeneity in this disease. Analysis of SNVs in relation to allele-specific copy-number changes pinpoints the common ancestor to a point prior to chemotherapy. For cases in which pre-and post-chemotherapy samples do show substantial differences, the timing of the divergence is near-synchronous with endoreduplication. Comparison across a large prospective cohort (62 treatment-naive, 58 chemotherapy-treated samples) reveals no significant differences in the overall mutation rate, mutation signatures, specific recurrent point mutations, or copy-number events in respect to chemotherapy status. In conclusion, whole-genome sequencing of samples obtained following neoadjuvant chemotherapy is representative of the genomic landscape of esophageal adenocarcinoma. Excluding these samples reduces the material available for cataloging and introduces a bias toward the earlier stages of cancer.

show abstract

mentioning

confidence: 99%

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In more recent years, prevalence of the latter has reached a plateau in high-prevalence countries such as the Netherlands and the UK 32. Given a lag time of about 10 years between the onset of Barrett's oesophagus and progression to severe dysplasia,33 the high and potentially rising incidence of oesophageal AC may also slowdown in these areas.…”

Section: Discussionmentioning

confidence: 99%

Global incidence of oesophageal cancer by histological subtype in 2012

Arnold

Soerjomataram

Ferlay

et al. 2014

Gut

1,161

950

View full text Add to dashboard Cite

show abstract

“…Worldwide, BE appears to be more prevalent in men than women, with various reports indicating a male to female ratio of 1.5–3:0 . Additionally, when present in women, BE tends to occur at elder age than in men .…”

Section: Introductionmentioning

confidence: 99%

Risk factors for Barrett's esophagus

Arora

Garber

Thota

2016

J of Digest Diseases

View full text Add to dashboard Cite

Barrett's esophagus (BE) is a well-recognized precursor of esophageal adenocarcinoma (EAC) and is defined as ≥1 cm segment of salmon-colored mucosa extending above the gastroesophageal junction into the tubular esophagus with biopsy confirmation of metaplastic replacement of the normal squamous epithelium by intestinal-type columnar epithelium. The incidence of both BE and EAC has been increasing over the past few decades. As a result, preventing the development of BE by identifying and understanding its modifiable and non-modifiable risk factors may help reduce the incidence of EAC. Over the recent past, a tremendous amount of progress has been made towards improving our knowledge of risk factors and pathogenesis of BE. This article reviews the evidence for the various risk factors for developing BE.

show abstract

The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off

Abstract: SUMMARY BackgroundBarrett's oesophagus (BO) is a risk factor for oesophageal adenocarcinoma (OAC). Several studies report increasing incidences of BO with substantial variation.

Cited by 44 publications

References 30 publications

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy

Global incidence of oesophageal cancer by histological subtype in 2012

Risk factors for Barrett's esophagus

Contact Info

Product

Resources

About